Opinion

Video

Assessing the Economic Burden of Under Diagnosed Dry Eye Disease

Key opinion leaders highlight the importance of identifying and treating dry eye disease to mitigate long-term economic burdens.

This is a video synopsis/summary of a Stakeholder Summit involving:

Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.

Kabiri estimates over 35 million Americans have undiagnosed or untreated dry eye disease (DED). With growing prevalence from aging demographics and digital device use, costs of uncontrolled DED will likely mushroom. Only a small subset of identified DED patients receive prescription therapy, representing huge unmet need.

Parekh notes the uncontrolled impact of DED on visual function and economic burden is comparable to retinal disease and glaucoma. Even after otherwise successful cataract surgery, residual DED impairs outcomes. Growing prevalence with prolonged device use raises the societal impact of DED. Comprehensive payer coverage and peer education around the rising prominence of DED will be key.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.

Related Videos
1 KOL is featured in this series.
Screenshot of an interview with Amir Ali, PharmD, BCOP
1 expert in this video
1 expert in this video
Dr Cesar Davila-Chapa
1 expert in this video
1 expert in this video
4 KOLs are featured in this series
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo